secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2023-02-23T23:59:59+00:00
Accession:  0000950170-23-004092
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q4 net loss $101.6M; CEO Scangos retiring, CFO Horn resigning
-------------------------------------------------------------------------

- Q4 2022 revenue $49.4M vs $812.7M YoY; net loss $0.76/share vs net income $4.01/share.
- Full year 2022 revenue $1.6B, net income $515.8M ($3.89/share); cash & investments ~$2.4B.
- CEO George Scangos retiring April 3, 2023; succeeded by Marianne De Backer (Bayer exec).
- CFO Howard Horn resigning; replaced by Sung Lee, 20-year biotech veteran.
- Key pipeline catalysts: HBV data H1 2023, influenza PENINSULA data mid-2023, HDV data H2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/0000950170-23-004092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000095017023004092/vir-20230223.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-004092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer